NeurologyLive® Top Expert Interviews: December 2021

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

The NeurologyLive® team has been as busy as always bringing you the latest clinical news and research updates in neurology over the last month, including conducting several interviews with experts across a number of different and varying topics.

Among these included conversations on the costs associated with Alzheimer disease drug development with Jeffrey Cummings, MD, ScD; the recent approval of a new agent for generalized myasthenia gravis with James F. Howard, MD; the treatment of migraine in the emergency department with Anne-Maree Kelly, MD; a recent study that assessed the effectiveness of educational sleep medicine “boot camps” with Anita Shelgikar, MD, MHPE; and the highlights from the American Epilepsy Society Annual Meeting with Imad Najm, MD.

Click through the slides to see and read more from each expert’s exclusive conversation with NeurologyLive® in December 2021.

slideshow image

Click the image to watch this video, or the arrows to see the next video.

WATCH TIME: 3 minutes

The Substantial Costs Affiliated With Alzheimer Drug Development: Jeffrey Cummings, MD, ScD

"They’re [enrolled patients] the people we’re trying to help, but they’re also our allies in terms of drug development. That number—the size of it—was breathtaking to me.”

To better understand the costs of AD drug development in the private sector, lead author Jeffrey Cummings, MD, ScD, and colleagues collected data on 1099 nonanimal AD clinical trials from the last quarter-century. At the end of the analysis, cumulative expenditures on the research and development stage were estimated at $42.5 billion, with the greatest costs ($24,064 million; 57%) incurred during phase 3.1

Cummings, MD, ScD, professor of brain science, and director, Chambers-Grundy Center for Transformative Neuroscience, University of Nevada–Las Vegas, sat down with NeurologyLive® to discuss the reasoning behind his analysis and the most notable takeaways from the data. He also briefly mentioned the staggering number of patients that have been in these trials and the role they play in drug development.

To hear more insight from experts in the clinical care of patients and leading researchers in neurology, check out more of NeurologyLive®'s videos.

REFERENCES
1. Cummings JL, Goldman DP, Simmons-Stern NR, Ponton E. The costs of developing treatments for Alzheimer disease: a retrospective exploration. Alzheimer Dement. Published online September 28, 2021. doi:10.1002/alz.12450
2. FDA Approves New Treatment for Myasthenia Gravis. News release. FDA. December 17, 2021. Accessed January 13, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis
3. Kelly AM, Kuan WS, Chu KH, et al. Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)–a multinational observational study. Headache. 2021;61(10):1539-1552. doi:10.1111/head.14230?
4. Wappel SR, Scharf SM, Cohen L, et al. Improving sleep medicine education among health professions trainees. J Clin Sleep Med. 2021;17(12):2461-2466. doi:10.5664/jcsm.9456
Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.